Correlation Between Defence Therapeutics and Gemina Laboratories

Can any of the company-specific risk be diversified away by investing in both Defence Therapeutics and Gemina Laboratories at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Defence Therapeutics and Gemina Laboratories into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Defence Therapeutics and Gemina Laboratories, you can compare the effects of market volatilities on Defence Therapeutics and Gemina Laboratories and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Defence Therapeutics with a short position of Gemina Laboratories. Check out your portfolio center. Please also check ongoing floating volatility patterns of Defence Therapeutics and Gemina Laboratories.

Diversification Opportunities for Defence Therapeutics and Gemina Laboratories

-0.35

Correlation Coefficient

Defence Therapeutics  Gemina Laboratories

Very good diversification

The 3 months correlation between Defence and Gemina is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Defence Therapeutics and Gemina Laboratories in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gemina Laboratories and Defence Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Defence Therapeutics are associated (or correlated) with Gemina Laboratories. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gemina Laboratories has no effect on the direction of Defence Therapeutics i.e., Defence Therapeutics and Gemina Laboratories go up and down completely randomly.

Pair Corralation between Defence Therapeutics and Gemina Laboratories

Assuming the 90 days horizon Defence Therapeutics is expected to under-perform the Gemina Laboratories. But the otc stock apears to be less risky and, when comparing its historical volatility, Defence Therapeutics is 2.15 times less risky than Gemina Laboratories. The otc stock trades about -0.05 of its potential returns per unit of risk. The Gemina Laboratories is currently generating about 0.16 of returns per unit of risk over similar time horizon. If you would invest  31.00  in Gemina Laboratories on September 12, 2024 and sell it today you would earn a total of  24.00  from holding Gemina Laboratories or generate 77.42% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.44%
Values	Daily Returns

Defence Therapeutics  vs.  Gemina Laboratories

Defence Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Defence Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's technical and fundamental indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Gemina Laboratories

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Gemina Laboratories are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak fundamental drivers, Gemina Laboratories reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Defence Therapeutics and Gemina Laboratories

The main advantage of trading using opposite Defence Therapeutics and Gemina Laboratories positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Defence Therapeutics position performs unexpectedly, Gemina Laboratories can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gemina Laboratories will offset losses from the drop in Gemina Laboratories' long position.

The idea behind Defence Therapeutics and Gemina Laboratories pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.